Haleon (NYSE: HLN) details total voting rights and treasury shares

Rhea-AI Filing Summary

Haleon plc provided an update on its total voting rights and share capital. As at 28 February 2026, the company had 8,952,353,648 issued ordinary shares of £0.01 each, with 43,969,144 held as treasury shares. This leaves 8,908,384,504 ordinary shares carrying voting rights.

The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose interests or changes in interests under the FCA's Disclosure Guidance and Transparency Rules.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	02 March 2026 - “Total Voting Rights and Capital”

99.1

Haleon plc: Total Voting Rights and Capital

02 March 2026: As at 28 February 2026 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,952,353,648 ordinary shares of £0.01 each, of which 43,969,144 are held as treasury shares.

Therefore, the number of ordinary shares with voting rights is 8,908,384,504 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notifiable interests in Haleon may be sent to: company.secretary@haleon.com

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: March 02, 2026	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What total number of shares has Haleon plc (HLN) issued?

Haleon plc has issued 8,952,353,648 ordinary shares of £0.01 each as at 28 February 2026. This figure includes shares held in treasury, which do not carry voting rights but remain part of the issued share capital.

How many Haleon plc (HLN) shares currently carry voting rights?

Haleon plc reports 8,908,384,504 ordinary shares with voting rights as at 28 February 2026. This number results from deducting treasury shares from issued shares and is the denominator for regulatory disclosure calculations under FCA transparency rules.

How many Haleon plc (HLN) shares are held in treasury?

Haleon plc holds 43,969,144 ordinary shares as treasury shares as at 28 February 2026. Treasury shares are issued but do not carry voting rights, so they are excluded when calculating total voting rights for disclosure purposes.

How should Haleon plc (HLN) shareholders use the voting rights information?

Shareholders should use 8,908,384,504 voting shares as the denominator when determining whether they must notify their interest, or any change in interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules governing major shareholdings.

Who is the company secretary for Haleon plc (HLN)?

The company secretary of Haleon plc is Amanda Mellor. The filing shows her signing on behalf of the company and lists her as the contact point for notifiable interests via the dedicated company secretary email address provided by Haleon.

Where can investors send notifiable interests in Haleon plc (HLN)?

Notifiable interests in Haleon plc may be sent to company.secretary@haleon.com. This email address is provided for shareholders and others who must notify their interests or changes in interests under applicable FCA disclosure and transparency requirements.

What type of business is Haleon plc (HLN) engaged in?

Haleon plc is described as a global leader in consumer health, focused on delivering better everyday health. Its portfolio spans oral health, vitamins and supplements, pain relief, respiratory, digestive, and therapeutic skin health through well-known brands like Advil, Centrum, Panadol, Sensodyne and Voltaren.